ZyVersa Therapeutics Secures $1M in Highly Dilutive Convertible Note and Warrant Offering

summarizeSummary

ZyVersa Therapeutics raised $1 million through a private placement of convertible notes and warrants, providing working capital but introducing significant potential dilution for shareholders.

check_boxKey Events

• Secured $1 Million Financing

  ZyVersa Therapeutics, Inc. entered into a Securities Purchase Agreement on February 27, 2026, to issue and sell convertible promissory notes in an aggregate principal amount of $1 million to accredited investors.

• Issued Convertible Notes with Discounted Conversion

  The notes bear 10% annual interest, mature in 12 months, and are convertible into common stock at 80% of a future qualified offering price or 80% of the lowest 10-day volume-weighted average price (VWAP), subject to a floor price of $0.02 per share.

• Issued Series A-4 Common Stock Purchase Warrants

  The company also issued warrants, exercisable after six months for five years, with an exercise price of 110% of a qualified offering price or 110% of a 5-day VWAP, further increasing potential dilution.

• Proceeds for Working Capital

  The net proceeds from this offering are designated for general working capital purposes.

auto_awesomeAnalysis

ZyVersa Therapeutics, a nano-cap company, has secured $1 million through a private placement of convertible promissory notes and warrants. This capital raise, while providing essential working capital, comes with highly dilutive terms for existing shareholders. The notes are convertible at a significant discount to market price (80% of future offering or VWAP, with a $0.02 floor), and the accompanying warrants further increase potential dilution. For a company of this size, such terms indicate a challenging financing environment and could place considerable pressure on the stock price due to the overhang of future conversions and exercises.